How are ALGN strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ALGN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 55.57%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,585.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a ALGN strangle?

The breakeven for the ALGN strangle priced on this page is roughly $144.15 and $190.85 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ALGN market-implied 1-standard-deviation expected move is approximately 15.93%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current ALGN implied volatility affect this strangle?

ALGN ATM IV is at 55.57% with IV rank near 59.03%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

ALGN Strangle Strategy

ALGN (Align Technology, Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.

Align Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry. The company's operations are divided into two main business units: "Clear Aligner" and "Scanners and Services." The Clear Aligner segment offers a variety of solutions. Its comprehensive products include the full Invisalign treatment for teenage patients, designed to address complex orthodontic needs such as mandibular advancement, patient compliance tracking, and managing tooth eruption. It also features specialized Invisalign First Phase I and Phase 2 packages for younger children, typically aged seven to ten, who have mixed dentition (a combination of primary and permanent teeth). Beyond these, the segment provides non-comprehensive aligner options like Invisalign moderate, lite, express, and Invisalign Go.

ALGN (Align Technology, Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $12.78B, a trailing P/E of 29.65, a beta of 1.67 versus the broader market, a 52-week range of 122-208.31, average daily share volume of 1.0M, a public-listing history dating back to 2001, approximately 21K full-time employees. These structural characteristics shape how ALGN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.67 indicates ALGN has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on ALGN?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current ALGN snapshot

As of June 30, 2026, spot at $168.50, ATM IV 55.57%, IV rank 59.03%, expected move 15.93%. The strangle on ALGN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 31-day expiry.

Why this strangle structure on ALGN specifically: ALGN IV at 55.57% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 15.93% (roughly $26.84 on the underlying). The 31-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ALGN expiries trade a higher absolute premium for lower per-day decay. Position sizing on ALGN should anchor to the underlying notional of $168.50 per share and to the trader's directional view on ALGN stock.

ALGN strangle setup

The ALGN strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ALGN near $168.50, the first option leg uses a $175.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ALGN chain at a 31-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ALGN shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$175.00	$8.45
Buy 1	Put	$160.00	$7.40

ALGN strangle risk and reward

Net Premium / Debit: -$1,585.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$1,585.00
Breakeven(s): $144.15, $190.85
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

ALGN strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on ALGN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$14,414.00
$37.27	-77.9%	+$10,688.48
$74.52	-55.8%	+$6,962.96
$111.78	-33.7%	+$3,237.45
$149.03	-11.6%	-$488.07
$186.29	+10.6%	-$456.41
$223.54	+32.7%	+$3,269.11
$260.80	+54.8%	+$6,994.62
$298.05	+76.9%	+$10,720.14
$335.31	+99.0%	+$14,445.66

When traders use strangle on ALGN

Strangles on ALGN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ALGN chain.

ALGN thesis for this strangle

The market-implied 1-standard-deviation range for ALGN extends from approximately $141.66 on the downside to $195.34 on the upside. A ALGN long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ALGN IV rank near 59.03% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on ALGN should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ALGN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ALGN-specific events.

ALGN strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ALGN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ALGN alongside the broader basket even when ALGN-specific fundamentals are unchanged. Always rebuild the position from current ALGN chain quotes before placing a trade.

Frequently asked questions

What is a strangle on ALGN?: A strangle on ALGN is the strangle strategy applied to ALGN (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ALGN stock trading near $168.50, the strikes shown on this page are snapped to the nearest listed ALGN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ALGN strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ALGN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 55.57%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,585.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ALGN strangle?: The breakeven for the ALGN strangle priced on this page is roughly $144.15 and $190.85 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ALGN market-implied 1-standard-deviation expected move is approximately 15.93%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on ALGN?: Strangles on ALGN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ALGN chain.
How does current ALGN implied volatility affect this strangle?: ALGN ATM IV is at 55.57% with IV rank near 59.03%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.